Last update 28 Sep 2024
GQ-1005
Last update 28 Sep 2024
Overview
Basic Info
Drug Type Antibody drug conjugate (ADC) |
Synonyms GQ 1005, GQ-1005, GQ1005 |
Target |
Mechanism HER2 modulators(Receptor protein-tyrosine kinase erbB-2 modulators) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Structure
Boost your research with our XDC technology data.
login
or
Related
2
Clinical Trials associated with GQ-1005A Phase 1, First-In-Human, Multicenter, Open-Label,Dose-Escalation and Extension Study of GQ1005 in Subjects With HER2-Expressing Advanced Solid Tumors
GQ1005在HER2表达的晚期实体瘤受试者的首次人体、多中心、开放、剂量递增和扩展I期临床研究
[Translation] A first-in-human, multicenter, open-label, dose-escalation and expansion phase I clinical study of GQ1005 in subjects with HER2-expressing advanced solid tumors
100 Clinical Results associated with GQ-1005
Login to view more data
100 Translational Medicine associated with GQ-1005
Login to view more data
100 Patents (Medical) associated with GQ-1005
Login to view more data
100 Deals associated with GQ-1005
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| HER2 Positive Solid Tumors | Phase 1 | CN | 23 Nov 2022 | |
| HER2-Low Breast Carcinoma | Phase 1 | - | - | |
| HER2-Low Gastric Cancer | Phase 1 | - | - | |
| Breast Cancer | Preclinical | CN | 25 Feb 2022 | |
| Stomach Cancer | Preclinical | CN | 25 Feb 2022 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
NCT06154343 (ESMO2024) Manual  | Phase 1 | 165 | itqwblpcpn(ctvbminefu) = zlekcxnkpq ahxetcizfw (fwnlemmfep ) View more | Positive | 14 Sep 2024 | ||
(HER2 low BC) | itqwblpcpn(ctvbminefu) = weqvswibjy ahxetcizfw (fwnlemmfep, 6.1 - NA) View more | ||||||
NCT06154343 (WCLC2024) Manual | Phase 1 | HER2 Positive Solid Tumors | HER2 mutant non-small cell lung cancer ERBB2 Mutation (Activating) | HER2 Expression | 131 | GQ1005 | jwxozscydz(cpdlxxzgmk) = odtystnbsw fuxnrwmzou (xejbyxxiaf ) View more | Positive | 10 Sep 2024 |
GQ1005 (advanced HER2-mutated NSCLC) | jwxozscydz(cpdlxxzgmk) = rtaymnzrtj fuxnrwmzou (xejbyxxiaf ) View more | ||||||
NCT06154343 (AACR2024) Manual | Phase 1 | Solid tumor HER2 Positive | HER2 Expression | 46 | vdhjnrdxqp(olnnqmcmtb) = gcgiocfnab ymnkogmlai (zefgriitad ) View more | Positive | 05 Apr 2024 |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free